Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:DNLI NASDAQ:FATE NASDAQ:HALO NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$3.31+8.9%$2.79$0.87▼$6.14$307.68M0.991.13 million shs1.16 million shsDNLIDenali Therapeutics$17.25+3.5%$14.84$10.57▼$33.33$2.44B1.31.93 million shs1.56 million shsFATEFate Therapeutics$1.54+4.8%$1.15$0.66▼$3.50$169.54M2.343.12 million shs1.06 million shsHALOHalozyme Therapeutics$66.47-0.8%$71.63$42.01▼$79.50$7.84B1.162.23 million shs1.42 million shsRVMDRevolution Medicines$54.01-0.2%$42.78$29.17▼$62.40$10.11B1.272.13 million shs2.13 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector0.00%+0.66%+0.33%+87.65%-39.08%DNLIDenali Therapeutics0.00%+8.39%+30.67%+20.46%-39.62%FATEFate Therapeutics0.00%-10.09%+52.76%+27.83%-54.49%HALOHalozyme Therapeutics0.00%+4.57%-13.85%+19.87%+27.41%RVMDRevolution Medicines0.00%+12.15%+24.25%+40.81%+7.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$3.31+8.9%$2.79$0.87▼$6.14$307.68M0.991.13 million shs1.16 million shsDNLIDenali Therapeutics$17.25+3.5%$14.84$10.57▼$33.33$2.44B1.31.93 million shs1.56 million shsFATEFate Therapeutics$1.54+4.8%$1.15$0.66▼$3.50$169.54M2.343.12 million shs1.06 million shsHALOHalozyme Therapeutics$66.47-0.8%$71.63$42.01▼$79.50$7.84B1.162.23 million shs1.42 million shsRVMDRevolution Medicines$54.01-0.2%$42.78$29.17▼$62.40$10.11B1.272.13 million shs2.13 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector0.00%+0.66%+0.33%+87.65%-39.08%DNLIDenali Therapeutics0.00%+8.39%+30.67%+20.46%-39.62%FATEFate Therapeutics0.00%-10.09%+52.76%+27.83%-54.49%HALOHalozyme Therapeutics0.00%+4.57%-13.85%+19.87%+27.41%RVMDRevolution Medicines0.00%+12.15%+24.25%+40.81%+7.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.13Hold$4.1725.88% UpsideDNLIDenali Therapeutics 3.06Buy$33.5094.20% UpsideFATEFate Therapeutics 2.00Hold$3.30114.29% UpsideHALOHalozyme Therapeutics 2.42Hold$72.899.66% UpsideRVMDRevolution Medicines 2.93Moderate Buy$76.6741.95% UpsideCurrent Analyst Ratings BreakdownLatest ALEC, DNLI, FATE, RVMD, and HALO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025HALOHalozyme TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$80.00 ➝ $79.0010/17/2025RVMDRevolution MedicinesNational BanksharesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$80.0010/17/2025RVMDRevolution MedicinesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$72.00 ➝ $76.0010/17/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$77.0010/15/2025RVMDRevolution MedicinesStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$85.0010/15/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$90.0010/14/2025HALOHalozyme TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold10/14/2025HALOHalozyme TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Market Perform$70.0010/8/2025ALECAlectorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025DNLIDenali TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025FATEFate TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M3.33N/AN/A$1.29 per share2.57DNLIDenali Therapeutics$330.53M7.63N/AN/A$8.53 per share2.02FATEFate Therapeutics$13.63M13.03N/AN/A$2.80 per share0.55HALOHalozyme Therapeutics$1.02B7.66$4.61 per share14.41$2.86 per share23.24RVMDRevolution Medicines$11.58M871.86N/AN/A$13.47 per share4.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.16N/AN/AN/A-142.10%-112.06%-26.37%11/5/2025 (Estimated)DNLIDenali Therapeutics-$422.77M-$2.80N/AN/AN/AN/A-40.79%-36.39%11/5/2025 (Estimated)FATEFate Therapeutics-$186.26M-$1.45N/AN/AN/A-2,025.05%-50.95%-36.76%11/11/2025 (Estimated)HALOHalozyme Therapeutics$444.09M$4.3715.2110.690.3647.28%150.85%29.19%10/30/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)Latest ALEC, DNLI, FATE, RVMD, and HALO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025FATEFate Therapeutics-$0.31N/AN/AN/A$1.63 millionN/A11/5/2025Q3 2025ALECAlector-$0.40N/AN/AN/A$3.49 millionN/A11/5/2025Q3 2025DNLIDenali Therapeutics-$0.76N/AN/AN/A$1.00 millionN/A11/5/2025Q3 2025RVMDRevolution Medicines-$1.39N/AN/AN/A$1.81 millionN/A10/30/2025Q3 2025HALOHalozyme Therapeutics$1.63N/AN/AN/A$339.18 millionN/A8/12/2025Q2 2025FATEFate Therapeutics-$0.35-$0.29+$0.06-$0.29$1.16 million$1.91 million8/11/2025Q2 2025DNLIDenali Therapeutics-$0.74-$0.72+$0.02-$0.72$5.64 millionN/A8/7/2025Q2 2025ALECAlector-$0.45-$0.30+$0.15-$0.30$2.76 million$7.87 million8/6/2025Q2 2025RVMDRevolution Medicines-$0.94-$1.31-$0.37-$1.31$0.50 millionN/A8/5/2025Q2 2025HALOHalozyme Therapeutics$1.23$1.54+$0.31$1.33$282.66 million$325.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.133.783.78DNLIDenali Therapeutics0.0110.2710.27FATEFate TherapeuticsN/A8.048.04HALOHalozyme Therapeutics4.548.367.01RVMDRevolution Medicines0.1311.7911.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%DNLIDenali Therapeutics92.92%FATEFate Therapeutics97.54%HALOHalozyme Therapeutics97.79%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipALECAlector9.70%DNLIDenali Therapeutics12.50%FATEFate Therapeutics5.51%HALOHalozyme Therapeutics2.90%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270101.21 million91.39 millionOptionableDNLIDenali Therapeutics430146.21 million127.94 millionOptionableFATEFate Therapeutics550115.33 million108.98 millionOptionableHALOHalozyme Therapeutics390116.97 million113.57 millionOptionableRVMDRevolution Medicines250186.93 million171.60 millionOptionableALEC, DNLI, FATE, RVMD, and HALO HeadlinesRecent News About These CompaniesRevolution Medicines (NASDAQ:RVMD) Shares Gap Up - Should You Buy?October 18 at 11:51 AM | marketbeat.comRevolution Medicines' (RVMD) Outperform Rating Reiterated at WedbushOctober 18 at 8:39 AM | marketbeat.comWedbush Reiterates Revolution Medicines (RVMD) Outperform RecommendationOctober 18 at 7:03 AM | msn.comTD Asset Management Inc Buys 181,724 Shares of Revolution Medicines, Inc. $RVMDOctober 18 at 4:29 AM | marketbeat.comRevolution Medicines stock surges after FDA grants priority voucherOctober 17 at 3:59 PM | za.investing.comRevolution Medicines price target raised to $80 from $78 at BofAOctober 17 at 3:59 PM | msn.comAchieve, Disc, Revolution among winners of initial FDA national priority vouchersOctober 17 at 7:33 AM | msn.comWCM Investment Management LLC Grows Stock Position in Revolution Medicines, Inc. $RVMDOctober 17 at 5:35 AM | marketbeat.com6,116 Shares in Revolution Medicines, Inc. $RVMD Bought by Bayforest Capital LtdOctober 17 at 4:45 AM | marketbeat.comRevolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot ProgramOctober 16, 2025 | globenewswire.comRevolution Medicines (NASDAQ:RVMD) Insider Sells $1,213,500.00 in StockOctober 16, 2025 | marketbeat.comInsider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells 25,000 Shares of StockOctober 16, 2025 | insidertrades.com8,423 Shares in Revolution Medicines, Inc. $RVMD Bought by Maryland State Retirement & Pension SystemOctober 15, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Earns "Sell (D-)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comDid Leadership Moves Just Shift Revolution Medicines' (RVMD) Investment Narrative Ahead of Key Launches?October 7, 2025 | finance.yahoo.comRevolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Moderate Buy" by AnalystsOctober 4, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Makes New $1.98 Million Investment in Revolution Medicines, Inc. $RVMDOctober 3, 2025 | marketbeat.comRevolution Medicines, Inc. (RVMD) Insider Sells SharesOctober 2, 2025 | insidermonkey.comRevolution Medicines Shows Improved Relative Strength; Still Shy Of BenchmarkSeptember 30, 2025 | msn.comRevolution Medicines, Inc.: Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development OfficerSeptember 29, 2025 | finanznachrichten.deRevolution Medicines appoints Alan Sandler as CDOSeptember 29, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Tesla: 3 Reasons October’s Earnings Will Make or Break the StockBy Sam Quirke | September 23, 2025ALEC, DNLI, FATE, RVMD, and HALO Company DescriptionsAlector NASDAQ:ALEC$3.31 +0.27 (+8.88%) Closing price 04:00 PM EasternExtended Trading$3.26 -0.05 (-1.39%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Denali Therapeutics NASDAQ:DNLI$17.25 +0.59 (+3.54%) Closing price 04:00 PM EasternExtended Trading$17.65 +0.40 (+2.31%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Fate Therapeutics NASDAQ:FATE$1.54 +0.07 (+4.76%) Closing price 04:00 PM EasternExtended Trading$1.52 -0.02 (-1.30%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Halozyme Therapeutics NASDAQ:HALO$66.47 -0.56 (-0.84%) Closing price 04:00 PM EasternExtended Trading$66.05 -0.42 (-0.63%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Revolution Medicines NASDAQ:RVMD$54.01 -0.09 (-0.17%) Closing price 04:00 PM EasternExtended Trading$54.79 +0.78 (+1.44%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
